A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : JAK2

Search Conditions:
Search Keyword : JAK2
Search Method : Exact match.
Research Area:

Results:  
Hit abbr.: 2 kinds.
(Click one to see its hit entries.)

(Appearance freq, Descending)
Abbreviation: JAK2
Appearance Frequency: 1263 time(s)
Long forms: 26

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
Janus kinase 2
(1078 times)
Neoplasms
(154 times)
STAT3 (195 times)
PV (73 times)
ET (67 times)
1994 Identification of JAK protein tyrosine kinases as signaling molecules for prolactin. Functional analysis of prolactin receptor and prolactin-erythropoietin receptor chimera expressed in lymphoid cells.
Janus-activated kinase 2
(79 times)
Neoplasms
(31 times)
STAT3 (33 times)
IL (6 times)
IFN-gamma (4 times)
1998 Differentiation inducers modulate cytokine signaling pathways in a murine erythroleukemia cell line.
Janus tyrosine kinase 2
(39 times)
Endocrinology
(9 times)
STAT3 (5 times)
EPO (4 times)
EPOR (3 times)
1995 Characterization of growth hormone-induced tyrosine-phosphorylated proteins in mouse cells that express GH receptors.
JAK2V617F
(23 times)
Neoplasms
(7 times)
PV (7 times)
MPN (6 times)
MPNs (5 times)
2005 Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
Janus kinase 2 gene
(15 times)
Medicine
(4 times)
CALR (5 times)
ET (2 times)
MPN (2 times)
2009 The JAK2(V617F) tyrosine kinase mutation in blood donors with upper-limit haematocrit levels.
Janus-family tyrosine kinases 2
(3 times)
Endocrinology
(1 time)
CIRI (1 time)
EA (1 time)
EPOR (1 time)
2012 Growth hormone-induced JAK2 signaling and GH receptor down-regulation: role of GH receptor intracellular domain tyrosine residues.
JAK2WT
(2 times)
Hematology
(1 time)
MPNs (2 times)
LOH (1 time)
2014 Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice.
janus kinase 2 mutation
(2 times)
Neoplasms
(1 time)
AKT (1 time)
FDCP-EpoR (1 time)
PV (1 time)
2008 The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Janus kinase type 2
(2 times)
Pulmonary Medicine
(1 time)
AML (1 time)
CML (1 time)
ET (1 time)
2011 Clinical and laboratory features of myelofibrosis and limitations of current therapies.
10  Janus protein tyrosine kinase 2
(2 times)
Cell Biology
(2 times)
Bax (1 time)
Bcl-2 (1 time)
EPO (1 time)
2014 The osteogenic effect of erythropoietin on human mesenchymal stromal cells is dose-dependent and involves non-hematopoietic receptors and multiple intracellular signaling pathways.
11  phospho-janus-activated kinase 2
(2 times)
General Surgery
(1 time)
FITC (1 time)
PI (1 time)
rhEPO (1 time)
2013 Recombinant human erythropoietin attenuates neuronal apoptosis and cognitive defects via JAK2/STAT3 signaling in experimental endotoxemia.
12  prolactin-Janus kinase 2
(2 times)
Endocrinology
(1 time)
ATM (1 time)
Hsp90 (1 time)
PRL (1 time)
2018 ATM Is Required for the Prolactin-Induced HSP90-Mediated Increase in Cellular Viability and Clonogenic Growth After DNA Damage.
13  (LEPR)-Janus kinase 2
(1 time)
Endocrinology
(1 time)
ASO (1 time)
IRTK (1 time)
LEPR (1 time)
2013 Tub has a key role in insulin and leptin signaling and action in vivo in hypothalamic nuclei.
14  IL-6-Janus kinase 2
(1 time)
Molecular Biology
(1 time)
HR (1 time)
IL-6 (1 time)
2015 Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.
15  IRS-1-Janus Kinase-2
(1 time)
Endocrinology
(1 time)
GH (1 time)
IR (1 time)
IRS-1 (1 time)
2005 Reduction of adiposity with prolonged growth hormone treatment in old obese rats: effects on glucose handling and early insulin signaling.
16  JAK2 ph
(1 time)
Occupational Medicine
(1 time)
JAK/STAT (1 time)
MPL (1 time)
STAT3 (1 time)
2016 Activation of Janus kinase/signal transducers and activators of transcription pathway involved in megakaryocyte proliferation induced by vanadium resembles some aspects of essential thrombocythemia.
17  JAK2 tyrosine kinase mutation
(1 time)
Hematology
(1 time)
--- 2006 New insights into the pathogenesis and drug treatment of myelofibrosis.
18  JAK2 V617F mutation
(1 time)
Internal Medicine
(1 time)
ET (1 time)
SEC (1 time)
2011 Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia.
19  JAK2(V617F)-negative MPN: rs12339666
(1 time)
Biology
(1 time)
ET (1 time)
MPN (1 time)
2015 Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.
20  JAK2Deltahep
(1 time)
Natural Science Disciplines
(1 time)
GH (1 time)
GHtg (1 time)
GSTs (1 time)
2016 Hepatic Deletion of Janus Kinase 2 Counteracts Oxidative Stress in Mice.
21  JAK2KE
(1 time)
Molecular Biology
(1 time)
--- 1998 Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation.
22  Janus family kinase-2
(1 time)
Endocrinology
(1 time)
CIS (1 time)
SOCS-2 (1 time)
1999 Endotoxin-induced inhibition of growth hormone receptor signaling in rat liver in vivo.
23  Janus family protein kinase-2
(1 time)
Nephrology
(1 time)
ESPs (1 time)
UVC (1 time)
2007 Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo.
24  Janus kinase 2-signal transducer
(1 time)
Nephrology
(1 time)
GH (1 time)
IGF-1 (1 time)
2005 Growth hormone resistance in uremia, a role for impaired JAK/STAT signaling.
25  messengers--Janus kinase 2
(1 time)
Allergy and Immunology
(1 time)
EMSA (1 time)
IFN-gamma (1 time)
iNOS (1 time)
2003 Signalling events involved in interferon-gamma-inducible macrophage nitric oxide generation.
26  phosphor-Janus kinase 2
(1 time)
Neoplasms
(1 time)
5-aza-dC (1 time)
MSP (1 time)
SHP1 (1 time)
2016 Epigenetic regulation and anti-tumorigenic effects of SH2-containing protein tyrosine phosphatase 1 (SHP1) in human gastric cancer cells.